Maui Derm

Master the Clues that Mask Malignancy
October 02, 2021

Case-based observations offered clinicians real-world guidance on distinguishing underlying malignancies in the Therapeutic Hotline session at Maui Derm NP+PA Fall 2021.

Grand Rounds in Dermatology: Maui Derm NP+PA Fall 2021
October 02, 2021

In a grand rounds presentation at the Maui Derm NP+PA Fall 2021 conference, Seemal Desai, MD, FAAD, Raegan Hunt, MD, PhD, Ted Rosen, MD, and Matthew J. Zirwas, MD, discussed some of their challenging cases.

Pediatric Acne: What Signs are Concerning?
October 02, 2021

Which is more worrisome, neonatal or infantile acne? An expert answered this question and more during Maui Derm NP+PA Fall 2021’s update on acne and rosacea.

Management of Scarring Alopecia
October 02, 2021

In his presentation at Maui Derm NP+PA Fall 2021, Jerry Shapiro, MD, FAAD, shared his treatment protocols for lupus erythematosus, lichen planopilaris, folliculitis decalvans, and dissecting cellulitis.

Improve Allergen Diagnosis for Eczema, Contact Dermatitis
October 02, 2021

Learning to identify some well-disguised drivers of eczema and contact dermatitis can speed patients toward clear or almost clear, according to a presentation at Maui Derm NP+PA Fall 2021.

Latest on Infectious Disease at Maui Derm
October 01, 2021

Ted Rosen, MD, and Sheila Fallon Friedlander, MD, discuss infectious disease updates at the virtual Maui Derm NP+PA Fall 2021 conference.

Using Combination Therapies and Avoiding Subtypes for Rosacea
October 01, 2021

In this presentation on rosacea from Maui Derm NP+PA Fall 2021, Julie Harper, MD, explains why combination therapy is more effective and how classifying rosacea patients by subtype can lead to suboptimal treatments.

Psoriasis Updates: Comparing IL-23 and IL-17 Inhibitors, TNF Blockers
October 01, 2021

Factors include extent of disease, the latest findings on agents’ efficacy, and even patient weight.

SCC and BCC Updates from Maui Derm NP+PA Fall
October 01, 2021

At Maui Derm NP+PA Fall 2021, George Martin, MD, discussed his opinion on best treatment options for SCC in situ and cutaneous SCC at high risk for metastasis along with BCC that require special considerations.

What Patients Need to Know About New JAK Topical Inhibitor
September 30, 2021

Patients with mild to moderate AD have a new topical treatment option, but physicians will need to prepare for some focused conversations about safety.